Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer

Francis Igor Macedo,Emily Ryon,Shishir K. Maithel,Rachel M Lee,David A. Kooby,Ryan C. Fields,William G. Hawkins,Greg Williams,Ugwuji Maduekwe,Hong J. Kim,Syed A. Ahmad,Sameer H. Patel,Daniel E. Abbott,Patrick B. Schwartz,Sharon M. Weber,Charles R. Scoggins,Robert C. G. Martin,Vikas Dudeja,Dido Franceschi,Alan S. Livingstone,Nipun B. Merchant

Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer

2019

Objective:To compare the survival outcomes associated with clinical and pathological response in pancreatic ductal adenocarcinoma (PDAC) patients receiving neoadjuvant chemotherapy (NAC) with FOLFIRINOX (FLX) or gemcitabine/nab-paclitaxel (GNP) followed by curative-intent pancreatectomy.Background:N

Keywords:

Oncology
Surgery
FOLFIRINOX
Medicine
Pancreatic cancer
Gemcitabine
Internal medicine
Nab-paclitaxel
Chemotherapy
Pathological
pathological response
pancreatic ductal adenocarcinoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations